Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
44 hedge funds and large institutions have $45.3M invested in Kindred Biosciences, Inc. in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 3 closing their positions.
340% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 5
6% more capital invested
Capital invested by funds: $42.6M → $45.3M (+$2.71M)
0% more funds holding
Funds holding: 44 → 44 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$809K |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$722K |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
+$397K |
| 4 |
Renaissance Technologies
New York
|
+$312K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$295K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
-$1.14M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$351K |
| 3 |
CCM
Coldstream Capital Management
Bellevue,
Washington
|
-$72K |
| 4 |
LPL Financial
San Diego,
California
|
-$53K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$22.4K |
KIN Hedge Fund Activity: Q2 2016 in Review
44 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2016, worth a combined $45.3M — up 6.3% from $42.6M a quarter earlier.
Fund positioning in KIN was balanced in Q2 2016: 3 funds opened new positions, 3 closed out, 22 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $809K. The largest seller was Gruss Capital Management, exiting entirely with an estimated $1.14M sold.
- 44 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $45.3M of Kindred Biosciences, Inc. stock for Q2 2016, up 6.3% quarter-over-quarter.
- 3 funds opened new Kindred Biosciences, Inc. positions in Q2 2016 and 3 closed out, a net change of 0 holders.
- The largest Kindred Biosciences, Inc. buyer in Q2 2016 was Fidelity Investments, an estimated $809K added.
- The largest Kindred Biosciences, Inc. seller in Q2 2016 was Gruss Capital Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2016.